Clinical Trial Update: Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 vaccine trial MVA-MUC1-IL2 for prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• MVA-MUC1-IL2 (Modified vaccinia Ankara vector expressing MUC1 and interleukin-2)

Snippet

Sponsor: Transgene | Conditions: Prostatic Neoplasms | Phase 2 | Status: TERMINATED